Vaxcyte Inc
NASDAQ:PCVX
Vaxcyte Inc
Revenue
Vaxcyte Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaxcyte Inc
NASDAQ:PCVX
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Vaxcyte Inc
Glance View
Vaxcyte Inc. has carved a niche in the biotechnology industry with its focus on developing next-generation vaccines to tackle some of the most challenging infectious diseases. The company, headquartered in San Carlos, California, leverages its proprietary cell-free protein synthesis platform, XpressCF™, which enables the rapid production of complex proteins at scale. This technology forms the backbone of its vaccine development process, allowing Vaxcyte to bypass traditional cell-based methods that can be both time-consuming and costly. At the core of Vaxcyte's mission is its commitment to addressing unmet medical needs by enhancing the efficacy and safety profiles of vaccines, ultimately aiming to deliver superior alternatives to existing products on the market. Vaxcyte's business model is built on a strategic blend of research and development, partnerships, and intellectual property. The company invests heavily in R&D to advance its pipeline of vaccine candidates, with a particular emphasis on conjugate vaccines targeting bacterial infections such as pneumococcal diseases. Revenue generation is primarily driven through collaborations and licensing agreements with larger pharmaceutical companies that provide upfront payments, milestones, and potential royalties. These partnerships not only validate Vaxcyte’s scientific approach but also furnish the essential capital to sustain its innovative programs and bring its cutting-edge vaccines to market. As Vaxcyte continues to make strides in vaccine development, the company positions itself as a key player in the quest for more effective disease prevention solutions.
See Also
What is Vaxcyte Inc's Revenue?
Revenue
0
USD
Based on the financial report for Dec 31, 2024, Vaxcyte Inc's Revenue amounts to 0 USD.
You don't have any saved screeners yet